- Home
- ANAB
ANAB
AnaptysBio Inc.
as 03-28-2025 4:00pm EST
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 759.5M | IPO Year: | 2017 |
| Target Price: | $36.38 | AVG Volume (30 days): | 933.5K |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.21 - $41.31 | Next Earning Date: | 05-08-2025 |
| Revenue: | $91,280,000 | Revenue Growth: | 432.03% |
| Revenue Growth (this year): | -58.4% | Revenue Growth (next year): | 59.43% |
Stock Insider Trading Activity of AnaptysBio Inc. (ANAB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | ANAB | Director10% Owner | Dec 30 '24 | Buy | $12.93 | 85,098 | $1,099,642.42 | 7,860,180 |
Latest AnaptysBio Inc. News
ANAB Breaking Stock News: Dive into ANAB Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?
MT Newswires
5 days ago
AnaptysBio Approves $75 Million Buyback Plan; Shares Rise
GlobeNewswire
5 days ago
Anaptys Announces Stock Repurchase Plan
TipRanks
13 days ago
Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks
Zacks
a month ago
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
GlobeNewswire
a month ago
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
a month ago
Anaptys Announces Participation in March Investor Conferences
TipRanks
a month ago
Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data
Compare ANAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANAB AnaptysBio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.